[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Halozyme Therapeutic (HALO)

Halozyme Therapeutic (HALO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 7,867,858
  • Shares Outstanding, K 118,474
  • Annual Sales, $ 1,397 M
  • Annual Income, $ 316,890 K
  • EBIT $ 594 M
  • EBITDA $ 687 M
  • 60-Month Beta 0.89
  • Price/Sales 5.44
  • Price/Cash Flow 13.44
  • Price/Book 154.47

Options Overview Details

View History
  • Implied Volatility 36.07% (-8.77%)
  • Historical Volatility 34.57%
  • IV Percentile 34%
  • IV Rank 28.60%
  • IV High 52.70% on 08/05/25
  • IV Low 29.41% on 06/16/25
  • Expected Move (DTE 3) 1.79 (2.52%)
  • Put/Call Vol Ratio 0.05
  • Today's Volume 9,845
  • Volume Avg (30-Day) 1,027
  • Put/Call OI Ratio 0.41
  • Today's Open Interest 16,315
  • Open Int (30-Day) 13,506
  • Expected Range 69.15 to 72.72

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $1.76
  • Number of Estimates 4
  • High Estimate $1.81
  • Low Estimate $1.67
  • Prior Year $1.47
  • Growth Rate Est. (year over year) +19.73%

Price Performance

See More
Period Period Low Period High Performance
1-Month
62.38 +13.71%
on 05/01/26
73.89 -4.01%
on 05/12/26
+3.11 (+4.59%)
since 04/10/26
3-Month
61.33 +15.66%
on 03/27/26
81.51 -12.98%
on 02/17/26
-5.99 (-7.79%)
since 02/12/26
52-Week
47.50 +49.33%
on 05/14/25
82.22 -13.73%
on 02/09/26
+4.35 (+6.53%)
since 05/12/25

Most Recent Stories

More News
HALO Q1 Deep Dive: Royalty Expansion and Pipeline Progress Shape 2026 Outlook

HALO Q1 Deep Dive: Royalty Expansion and Pipeline Progress Shape 2026 Outlook

HALO : 70.93 (+6.81%)
Halozyme Therapeutics Q1 Earnings Call Highlights

Halozyme Therapeutics (NASDAQ:HALO) reported a sharp increase in first-quarter 2026 revenue and earnings, driven by continued growth in royalties from its ENHANZE drug-delivery platform, and announced...

HALO : 70.93 (+6.81%)
Halozyme Therapeutics: Q1 Earnings Snapshot

Halozyme Therapeutics: Q1 Earnings Snapshot

HALO : 70.93 (+6.81%)
Halozyme Therapeutics’s (NASDAQ:HALO) Q1 CY2026 Sales Top Estimates

Halozyme Therapeutics’s (NASDAQ:HALO) Q1 CY2026 Sales Top Estimates

HALO : 70.93 (+6.81%)
HALOZYME REPORTS FIRST QUARTER 2026 RESULTS AND REITERATES 2026 FINANCIAL GUIDANCE

Announcing New $1 billion Share Repurchase Program Projecting to Buy Back at Least $400 million in 2026

HALO : 70.93 (+6.81%)
Halozyme: A Decade of Platform Revenue Finally Gets Its First Real Stress Test

Barchart Research What to Expect from HALO Earnings HALO Generated May 8, 2026 Current Price $64.12 EPS Estimate $$1.46 Consensus Rating Moderate Buy Average Move 6.47% Halozyme: A Decade of Platform Revenue...

HALO : 70.93 (+6.81%)
Halozyme Therapeutics Earnings: What To Look For From HALO

Halozyme Therapeutics Earnings: What To Look For From HALO

HALO : 70.93 (+6.81%)
Halozyme: A Decade of Platform Revenue Finally Gets Its First Real Stress Test

Barchart Research What to Expect from HALO Earnings HALO Generated May 8, 2026 Current Price $64.12 EPS Estimate $$1.46 Consensus Rating Moderate Buy Average Move 6.47% Halozyme: A Decade of Platform Revenue...

HALO : 70.93 (+6.81%)
Halozyme: A Decade of Platform Revenue Finally Gets Its First Real Stress Test

Barchart Research What to Expect from HALO Earnings HALO Generated May 8, 2026 Current Price $64.12 EPS Estimate $$1.46 Consensus Rating Moderate Buy Average Move 6.47% Halozyme: A Decade of Platform Revenue...

HALO : 70.93 (+6.81%)
Halozyme Announces Global Collaboration and License Agreement with GSK to Develop Subcutaneous Formulations of Multiple Promising Oncology Targets

Marks first ENHANZE ® agreement to include ADC targets

HALO : 70.93 (+6.81%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 16% Buy with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Halozyme Therapeutics Inc. is a biopharmaceutical company, focused on the development and commercialization of novel treatments for oncology indications by targeting tumor microenvironment. The company's ENHANZE drug delivery technology helps in developing subcutaneous formulation of drugs. The company...

See More

Key Turning Points

3rd Resistance Point 80.37
2nd Resistance Point 77.13
1st Resistance Point 74.03
Last Price 70.93
1st Support Level 67.69
2nd Support Level 64.45
3rd Support Level 61.35

See More

52-Week High 82.22
Last Price 70.93
Fibonacci 61.8% 68.96
Fibonacci 50% 64.86
Fibonacci 38.2% 60.76
52-Week Low 47.50

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.